Amgen Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: Exceeded $10 billion, up 10% year-over-year.

Sales Growth: 22 products achieved double-digit sales growth; 17 products annualized over $1 billion in sales.

Non-GAAP Operating Margin: 48%.

Free Cash Flow: $3.5 billion generated in Q2.

R&D Spending: Increased by 10% year-over-year.

Dividend: Increased by 6% to $2.52 per share.

2026 Guidance: Revenue expected between $38.2 billion and $39.4 billion; non-GAAP EPS projected between $22.30 and $23.50.

2Strategic Updates and Business Highlights

Key Growth Drivers: Six key products driving growth include Repatha (37% growth), EVENITY (38%), TEZSPIRE (42%), Rare Disease portfolio (21%), Innovative Oncology (18%), and Biosimilars (29%).

Pipeline Progress: Late-stage assets like MariTide, Olpasiran, and Xaluritamig are advancing through Phase III development, targeting significant unmet medical needs.

Investment in Technology: Focus on AI and data analytics to enhance drug discovery and development processes.

Biosimilars: Strong performance with a 29% growth in biosimilars, generating $855 million in sales.

3Forward Guidance and Outlook

Revenue and EPS Guidance: Raised for 2026, reflecting strong execution in the first half of the year.

R&D Expense: Expected to grow in the high single digits, with ongoing Phase III trials for MariTide.

Operating Margin: Anticipated to remain around 45% to 46% for the full year.

4Bad News, Challenges, or Points of Concern

Prolia and XGEVA Sales: Combined sales decreased by 33% year-over-year due to increased competition from biosimilars.

Market Competition: New entrants in the PCSK9 market, including Merck's oral PCSK9, could impact Repatha's market share.

Monitoring Requirements: Concerns about the complexity of monitoring for IMDELLTRA and potential regulatory challenges.

5Notable Q&A Insights

Olpasiran Development: Questions about the trial design and endpoint selection; Amgen is confident in its study protocol and believes the exclusion of stroke from the primary endpoint will not adversely affect results.

MariTide Confidence: Executives expressed strong confidence in the Phase III trials, with a focus on managing side effects and improving patient adherence.

Dazodalibep Trials: Discussion on the differentiation of systemic versus symptomatic studies in Sjögren's disease, with a focus on addressing unmet needs in both populations.

Repatha Growth: Growth attributed to both existing prescribers and new primary care physicians, particularly for high-risk diabetes patients. Overall, Amgen's Q2 2026 results reflect strong financial performance and strategic positioning for future growth, despite facing competitive pressures and challenges in specific product lines.